Literature DB >> 31381387

Utilization Variation In Military Versus Civilian Care: Evidence From TRICARE.

Amelia M Bond1, Stephen D Schwab2.   

Abstract

The Defense Health Agency was established five years ago to integrate and centralize the provision of health care that had been managed separately by the Army, Navy, and Air Force. One favored proposal is to increase the use of private-sector or civilian health care providers. This study compared geographic variation in health care use (a common proxy for efficiency) between patients with a military (direct care) system and those with a civilian (purchased care) system primary care provider-both of which are offered in TRICARE Prime, a health plan that resembles a health maintenance organization. We found similar levels of variation across care utilization metrics with the exception of specialty care, in which the military sample had less variation than its civilian counterpart did. In the military system, risk-adjusted utilization levels were substantially lower for primary care visits and higher for specialty care visits, compared to these visits under the civilian system. Our findings suggest that expanding the use of the civilian system might not achieve the desired efficiencies. Rather, focusing on specialty care in the military system and expanding primary care in the civilian system could help achieve operational readiness and enhanced efficiency.

Entities:  

Keywords:  Acute Care; Military Health; access and use; geographic variation; primary care

Year:  2019        PMID: 31381387     DOI: 10.1377/hlthaff.2019.00298

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  1 in total

1.  In defense of Direct Care: Limiting access to military hospitals could worsen quality and safety.

Authors:  Cheryl K Zogg; Judith H Lichtman; Michael K Dalton; Peter A Learn; Andrew J Schoenfeld; Tracey Perez Koehlmoos; Joel S Weissman; Zara Cooper
Journal:  Health Serv Res       Date:  2021-11-08       Impact factor: 3.734

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.